Scripps
Offline
Online
IDH1 and IDH2 results in AML - Hagop Kantarjian
Date added (newest)
Greatest impact of immune checkpoint inhibitors in hematologic malignancies
Management of hematologic and solid tumor malignancies with PD-1 and PD-L1 monoclonal antibodies
Most common adverse events for PD-1 and PD-L1 monoclonal antibodies
Real world experience with the novel immune checkpoint inhibitors
Using Biomarkers in Immunotherapy in Head and Neck Cancer.
Pembrolizumab and nivolumab Immunotherapies Show Efficacy in Head and Neck Cancer
Immunotherapy is well tolerated in Head and Neck Cancer
Immunotherapy and future use of combination treatment in Head and Neck Cancer
Venetoclax in the management of CLL and where in the therapeutic algorithm it should play a role
eferred treatment regimen for patients who fail frontline therapy in CLL
Preferred salvage regimens for Ibrutinib and Idelalisib-Rituximab
Preferred frontline regimen for new CLL patients greater than 70 years
My videos
Greatest impact of immune checkpoint inhibitors in hemato...
Marin Xavier, MD of the Scripps Health discusses the greatest impact of immune checkpoint inhibitors in hematologic malignancies at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
www.scrippshealth.org/cancer
www.scrippshealth.org/cancer
